Studies with gastric cancer participants in addition to eligible participants · palliative participants with esophageal and GE‐junction carcinoma or gastric carcinoma
Summary of findings table (sensitivity analysis): interventions… showed no clear difference in studies with gastric cancer participants in addition to eligible… compared with gastric carcinoma; GRADE not reported.
1 finding from 1 review
Sensitivity analysis, meta‐regression analysis, first part · palliative participants with esophageal and GE‐junction carcinoma or gastric carcinoma
It is very uncertain whether summary of findings table (sensitivity analysis): interventions… changes sensitivity analysis, meta‐regression analysis, first part compared with gastric carcinoma (very low certainty).
1 finding from 1 review
Sensitivity analysis, only esophageal and GE‐junction cancer participants · palliative participants with esophageal and GE‐junction carcinoma or gastric carcinoma
Summary of findings table (sensitivity analysis): interventions… led to lower sensitivity analysis, only esophageal and GE‐junction cancer… compared with gastric carcinoma; GRADE not reported.
1 finding from 1 review
Sensitivity analysis, only gastric cancer participants · palliative participants with esophageal and GE‐junction carcinoma or gastric carcinoma
Summary of findings table (sensitivity analysis): interventions… showed no clear difference in sensitivity analysis, only gastric cancer participants compared with gastric carcinoma; GRADE not reported.
1 finding from 1 review
Sensitivity analysis, meta‐regression analysis, second part · palliative participants with esophageal and GE‐junction carcinoma or gastric carcinoma
Summary of findings table (sensitivity analysis): interventions… probably leads to lower sensitivity analysis, meta‐regression analysis, second part compared with gastric carcinoma (moderate certainty).
1 finding from 1 review
Overall survival · people with advanced gastric cancer
5‐FU/cisplatin/anthracycline combinations may leads to lower overall survival compared with 5‐FU/anthracycline combinations (without cisplatin) (low certainty).
1 finding from 1 review
Overall survival · people with advanced gastric cancer
Irinotecan probably leads to lower overall survival compared with non‐irinotecan‐containing regimens (moderate certainty).
1 finding from 1 review
Overall survival ‐ Substitutive comparisons · people with advanced gastric cancer
Irinotecan showed no clear difference in overall survival ‐ Substitutive comparisons compared with non‐irinotecan‐containing regimens (moderate certainty).
1 finding from 1 review
Overall survival ‐ Additive comparisons · people with advanced gastric cancer
Irinotecan showed no clear difference in overall survival ‐ Additive comparisons compared with non‐irinotecan‐containing regimens (low certainty).
1 finding from 1 review
Overall survival ‐ Other comparisons · people with advanced gastric cancer
It is very uncertain whether irinotecan changes overall survival ‐ Other comparisons compared with non‐irinotecan‐containing regimens (very low certainty).
1 finding from 1 review
Tumour response · people with advanced gastric cancer
Irinotecan may leads to higher tumour response compared with non‐irinotecan‐containing regimens (low certainty).
4 findings from 1 review
OR 1.72 [1.24, 2.4]
10 studies · 1266 participants
Low
OR 1.53 [0.93, 2.5]
6 studies · 756 participants
Low
OR 2.18 [1.25, 3.8]
3 studies · 345 participants
Low
Show 1 more finding
Progression‐free survival · people with advanced gastric cancer
Irinotecan leads to lower progression‐free survival compared with non‐irinotecan‐containing regimens (high certainty).
1 finding from 1 review
Progression‐free survival (PSF) · people with advanced gastric cancer
Irinotecan showed no clear difference in progression‐free survival ‐ Substitutive comparison compared with non‐irinotecan‐containing regimens (moderate certainty).
3 findings from 1 review
HR 0.85 [0.72, 1]
5 studies · 741 participants
Moderate
HR 0.51 [0.33, 0.77]
1 study · 90 participants
Moderate
HR 0.74 [0.66, 0.84]
2 studies · 809 participants
High
Treatment‐related death · people with advanced gastric cancer
Irinotecan showed no clear difference in treatment‐related death compared with non‐irinotecan‐containing regimens (low certainty).
1 finding from 1 review
Treatment discontinuation due to toxicity · people with advanced gastric cancer
It is very uncertain whether irinotecan changes treatment discontinuation due to toxicity compared with non‐irinotecan‐containing regimens (very low certainty).
1 finding from 1 review
Overall survival · people with advanced gastric cancer
Docetaxel leads to lower overall survival compared with non‐docetaxel‐containing regimens (high certainty).
1 finding from 1 review
Overall survival ‐ Substitutive comparisons · people with advanced gastric cancer
Docetaxel showed no clear difference in overall survival ‐ Substitutive comparisons compared with non‐docetaxel‐containing regimens (moderate certainty).
1 finding from 1 review
Overall survival ‐ Additive comparisons · people with advanced gastric cancer
Docetaxel probably leads to lower overall survival ‐ Additive comparisons compared with non‐docetaxel‐containing regimens (moderate certainty).
1 finding from 1 review
Overall survival ‐ Other comparisons · people with advanced gastric cancer
It is very uncertain whether docetaxel changes overall survival ‐ Other comparisons compared with non‐docetaxel‐containing regimens (very low certainty).
1 finding from 1 review
Tumour response · people with advanced gastric cancer
Docetaxel probably leads to higher tumour response compared with non‐docetaxel‐containing regimens (moderate certainty).
4 findings from 1 review
OR 1.37 [1.03, 1.83]
9 studies · 1820 participants
Moderate
OR 1.03 [0.71, 1.5]
4 studies · 525 participants
Moderate
OR 1.83 [1.45, 2.32]
4 studies · 1235 participants
High
Show 1 more finding